• Mashup Score: 4
    2021 Symposium | Lymphoma Hub - 2 year(s) ago

    Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease

    Source: lymphomahub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of lymphomahub
      lymphomahub

      👀 Did you see this? The Lymphoma Hub Satellite Symposium, which discussed sequencing of therapies in high-risk R/R #lymphoma and #CLL, was a great success! 🙌 You can view all the content on the Lymphoma Hub: 👉 https://t.co/dmrPMjcbpr 👈 #LymHubSS #16ICML #lymsm #leusm https://t.co/28RwhKj10i

  • Mashup Score: 0
    JACKPOT8: DZD4205 in peripheral T-cell lymphoma - 3 year(s) ago

    Won-Seog Kim, MD, PhD, Sungkyunkwan University, Seoul, South Korea, discusses preliminary safety and efficacy data from the Phase I/II JACKPOT8…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      📍JACKPOT8: DZD4205 in peripheral T-cell #Lymphoma📍 Won-Seog Kim discusses preliminary safety & efficacy data from the Phase I/II JACKPOT8 trial: https://t.co/93jkfrDn3l #16ICML @icmlugano #HemOnc #Lymsm #CTSM #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM

  • Mashup Score: 1
    Geltamo IMCL-2015: ibrutinib and rituximab in MCL - 3 year(s) ago

    Eva Giné, MD, Hospital Clínic de Barcelona, Barcelona, Spain, summarizes the results of the Phase II Geltamo IMCL-2015 (NCT02682641) trial,…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Phase II Geltamo IMCL-2015: ibrutinib and rituximab in indolent #MantleCellLymphoma Eva Giné of @hospitalclinic shares findings: https://t.co/lTZCM9Dsb0 #16ICML @icmlugano #HemOnc #Lymphoma #Lymsm #CTSM #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM

  • Mashup Score: 0
    MCL0208: identification of novel genomic prognostic factors - 3 year(s) ago

    Simone Ferrero, MD, University of Torino, Torino, Italy, shares an update on the Phase III MCL0208 trial (NCT02354313) of lenalidomide…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Simone Ferrero (@unito) talks on the Phase III MCL0208 trial of len vs. observation after rituximab induction for #MantleCellLymphoma Genomic prognostic factors with significant impact on PFS identified: https://t.co/xVxYhh4BjO #16ICML @icmlugano #HemOnc #Lymphoma #Lymsm #BCAM

  • Mashup Score: 0
    TRANSCEND-CLL-004: liso-cel in CLL - 3 year(s) ago

    William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the Phase I/II…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      TRANSCEND-CLL-004: liso-cel in #CLL w/ @wwierda (@MDAndersonNews): https://t.co/ncuBAMyE5L #16ICML @icmlugano #HemOnc #CLLsm #Leusm #CTSM #TrialUpdate #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM

  • Mashup Score: 3
    Is frontline R-CHOP still the standard of care for DLBCL? - 3 year(s) ago

    During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Laurie Sehn, The University of British Columbia, Vancouver, CA, and Grzegorz Nowakowski, Mayo Clinic, Rochester, US. We asked, Is frontline R-CHOP still the standard of care for DLBCL?

    Source: lymphomahub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of lymphomahub
      lymphomahub

      🎧 Listen to this #16ICML podcast with Laurie Sehn, @UBC and Grzegorz Nowakowski, @MayoClinic. We asked, Is frontline R-CHOP still the standard of care for DLBCL? 👉 https://t.co/5Qo1YHBnOq 👈 #lymsm #lymphoma https://t.co/p8P9QQFie3

  • Mashup Score: 1
    The CAR-HEMATOTOX model for CAR T-cell hematotoxicity in R/R LBCL - 3 year(s) ago

    Hematotocixity is a frequent adverse event related to chimeric antigen receptor (CAR) T-cell therapy. Despite an improvement in response rates in relapsed/refractory (R/R) B-cell malignancies, the utility of CAR T-cell therapy has been affected by its distinct toxicity profile.

    Source: lymphomahub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of lymphomahub
      lymphomahub

      📚 @KRejeski recently presented at #16ICML and published in @bloodjournal the CAR-HEMATOTOX model to predict severe neutropenia following CAR T cell therapy for #LBCL 👉 https://t.co/elTN6654ET 👈 #lymsm #lymphoma

  • Mashup Score: 0
    What’s new in mantle cell lymphoma? - 3 year(s) ago

    During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Martin Dreyling, Ludwig-Maximilians-Universität München, Munich, DE. We asked, What’s new in mantle cell lymphoma?

    Source: lymphomahub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of lymphomahub
      lymphomahub

      👀 During #16ICML the @lymphomahub spoke with Martin Dreyling, @LMU_Muenchen. We asked, What’s new in mantle cell lymphoma? 👉 https://t.co/pcKMz112ww 👈 #lymsm #lymphoma https://t.co/cypsklZvoa

Load More